BUDGET IMPACT ANALYSIS OF INTRODUCING FRUQUINTINIB FOR THE TREATMENT OF PREVIOUSLY TREATED METASTATIC COLORECTAL CANCER IN THE UNITED STATES FROM THE PAYER PERSPECTIVE

被引：0
|
作者：
Hernandez, L. G. [1 ]
Paly, V [1 ]
Li, S. [2 ]
Khanduri, P. [3 ]
Asfaw, A. A. [4 ]
Zou, D. [5 ]
机构：
[1] Takeda Pharmaceut America Inc, Lexington, MA USA
[2] Evidera, Toronto, ON, Canada
[3] Evidera, Waltham, MA USA
[4] Takeda Dev Ctr Amer Inc TDCA, Lexington, MA USA
[5] Evidera, San Francisco, CA USA
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE267
引用
收藏
页码：S106 / S106
页数：1
相关论文
共 50 条
  • [41] BUDGET IMPACT ANALYSIS OF BIRCH TRITERPENES FOR PATIENTS WITH EPIDERMOLYSIS BULLOSA FROM A UNITED STATES PERSPECTIVE
    Stevenson, A.
    Tao, C.
    Pinsonault, T.
    Kenney, J. T.
    Brody, P.
    Collins, C.
    Dorling, P.
    Lee, Wine L.
    VALUE IN HEALTH, 2024, 27 (12) : S123 - S124
  • [42] Budget impact of Ontruzant for the treatment of breast cancer and gastric cancer in the United States
    Huang, Min
    Singhal, Puneet
    Shinde, Reshma
    Wilkes, Sarah K.
    Nagda, Nirav
    Yi, Yunni
    Lucherini, Stefano
    CANCER RESEARCH, 2021, 81 (04)
  • [43] BUDGET IMPACT ANALYSIS OF ABIRATERONE ACETATE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS PREVIOUSLY TREATED WITH DOCETAXEL FROM THE PERSPECTIVE OF THE BRAZILIAN PRIVATE HEALTH CARE SYSTEM
    Vitale, V.
    Asano, E.
    Pereira, M. L.
    VALUE IN HEALTH, 2013, 16 (07) : A665 - A665
  • [44] Budget Impact Analysis of Introducing Elotuzumab in Combination with Lenalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: A US Payer Perspective
    Potluri, Ravi
    Bhandari, Hitesh
    Ranjan, Sandip
    Chen, Clara
    BLOOD, 2016, 128 (22)
  • [45] THE ECONOMIC IMPACT OF SWITCHING TO HERCEPTIN (TRASTUZUMAB) BIOSIMILAR FOR THE TREATMENT OF METASTATIC BREAST CANCER FROM A UK PAYER PERSPECTIVE
    Brown, D.
    Bozkaya, D.
    VALUE IN HEALTH, 2017, 20 (09) : A425 - A425
  • [46] ESTIMATING THE BUDGET IMPACT OF DAPAGLIFLOZIN FOR THE TREATMENT OF CHRONIC KIDNEY DISEASE FROM A UK PAYER PERSPECTIVE
    Darlington, Oliver
    McEwan, Phil
    Boyce, Rebecca
    Chen, Gengshi
    Martin, Becky
    Sorstadius, Elisabeth
    Sanchez, Juan Jose Garcia
    Rao, Naveen
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2021, 36 : 484 - 484
  • [47] BUDGET IMPACT OF LYBALVI® FOR THE TREATMENT OF SCHIZOPHRENIA AND BIPOLAR I DISORDER FROM A US PAYER PERSPECTIVE
    Doane, M.
    O'Sullivan, A. K.
    Ottino, K.
    Eichten, C.
    VALUE IN HEALTH, 2022, 25 (07) : S365 - S365
  • [48] Assessing health plan payer's budget impact of etranacogene dezaparvovec for the treatment of hemophilia B in the United States
    Wilson, Michele
    McDade, Cheryl
    Thiruvillakkat, Kris
    Rouse, Robert
    Sivamurthy, Krupa
    Yan, Songkai
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2024, 30 (08): : 805 - 816
  • [49] BUDGET IMPACT ANALYSIS OF LIPOSOMAL IRINOTECAN FOR TREATMENT OF METASTATIC ADENOCARCINOMA OF PANCREAS FOLLOWING PROGRESSION ON GEMCITABINE-BASED THERAPIES FROM GREEK PAYER'S PERSPECTIVE
    Chotzagiannoglou, V
    Kastanioti, C.
    Papazisis, G.
    Kouvelas, D.
    VALUE IN HEALTH, 2020, 23 : S450 - S450
  • [50] BUDGET IMPACT ANALYSIS OF USTEKINUMAB FOR THE TREATMENT OF MODERATE TO SEVERE CROHN'S DISEASE FROM A BRAZILIAN PRIVATE PAYER PERSPECTIVE
    Fioratti, C. O.
    Asano, E.
    Rosim, R. P.
    VALUE IN HEALTH, 2018, 21 : S82 - S82
12345